These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8882320)

  • 1. Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.
    Franchini G; Benson J; Gallo R; Paoletti E; Tartaglia J
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):407-8. PubMed ID: 8882320
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine against human T cell leukemia-lymphoma virus type I: progress and prospects.
    Bomford R; Kazanji M; De Thé G
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):403-5. PubMed ID: 8882319
    [No Abstract]   [Full Text] [Related]  

  • 3. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells.
    Zavala F; Rodrigues M; Rodriguez D; Rodriguez JR; Nussenzweig RS; Esteban M
    Virology; 2001 Feb; 280(2):155-9. PubMed ID: 11162829
    [No Abstract]   [Full Text] [Related]  

  • 4. Highly attenuated poxvirus vectors.
    Tartaglia J; Cox WI; Taylor J; Perkus M; Riviere M; Meignier B; Paoletti E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1445-7. PubMed ID: 1466978
    [No Abstract]   [Full Text] [Related]  

  • 5. A chemically defined production process for highly attenuated poxviruses.
    Jordan I; Northoff S; Thiele M; Hartmann S; Horn D; Höwing K; Bernhardt H; Oehmke S; von Horsten H; Rebeski D; Hinrichsen L; Zelnik V; Mueller W; Sandig V
    Biologicals; 2011 Jan; 39(1):50-8. PubMed ID: 21237672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing poxvirus vectors vaccine immunogenicity.
    García-Arriaza J; Esteban M
    Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of poxvirus vectored vaccines.
    Robertson JS
    Vaccine; 2013 Sep; 31(39):4259-60. PubMed ID: 23747453
    [No Abstract]   [Full Text] [Related]  

  • 8. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live attenuated virus vaccine against sheep pox.
    Sólyom F; Perenlei L; Roith J
    Acta Vet Acad Sci Hung; 1981; 28(4):389-98. PubMed ID: 6269410
    [No Abstract]   [Full Text] [Related]  

  • 10. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
    Gómez CE; Nájera JL; Krupa M; Esteban M
    Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.
    Kallel H; Kamen AA
    Biotechnol J; 2015 May; 10(5):741-7. PubMed ID: 25914340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal poxvirus vaccines: a comprehensive review.
    Bhanuprakash V; Hosamani M; Venkatesan G; Balamurugan V; Yogisharadhya R; Singh RK
    Expert Rev Vaccines; 2012 Nov; 11(11):1355-74. PubMed ID: 23249235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunization of mice against sarcosporidia (Sarcocystis muris) with attenuated sporocysts].
    Leier H; Boch J; Erber M
    Berl Munch Tierarztl Wochenschr; 1982 Jun; 95(12):231-5. PubMed ID: 6287998
    [No Abstract]   [Full Text] [Related]  

  • 15. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
    Karkhanis LU; Ross TM
    Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly attenuated poxviruses induce functional priming of neutrophils in vitro.
    Förster R; Wolf G; Mayr A
    Arch Virol; 1994; 136(1-2):219-26. PubMed ID: 8002789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.
    Franchini G; Tartaglia J; Markham P; Benson J; Fullen J; Wills M; Arp J; Dekaban G; Paoletti E; Gallo RC
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):307-13. PubMed ID: 7742044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxvirus vectors: cytoplasmic expression of transferred genes.
    Moss B
    Curr Opin Genet Dev; 1993 Feb; 3(1):86-90. PubMed ID: 8453278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological risks of adult T-cell leukemia at primary HTLV-I infection.
    Kannagi M; Ohashi T; Harashima N; Hanabuchi S; Hasegawa A
    Trends Microbiol; 2004 Jul; 12(7):346-52. PubMed ID: 15223062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.